Late at night, the Federal Reserve remained silent, but changed the market
Source: Wall Street Intelligence Circle
Trading Walsh doesn’t mean trading his answers, but trading his silence.
After Walsh’s second appearance, the market once again returned to a dangerous state:
The U.S. stock market declined across the board. Although the decline was not significant, the result was still a drop. Meanwhile, the U.S. Dollar Index held firm at the 101 level, and the 10-year U.S. Treasury yield once again approached the 4.50% warning line.
His seemingly calm speech, however, fired three shots at the market.
First Shot (Dovish on the outside, hawkish at the core): Dove on the surface, but no real shift
Walsh made some dovish remarks. For example, inflation expectations have dropped, and inflation risks have lessened. On the surface, this sounds favorable to bonds, technology stocks, and gold, because it implies the Federal Reserve may not rush to raise rates—but you can’t just listen to that part. At the same time, he did not rule out a rate hike in July, did not provide any forward guidance on rates, emphasized that the 2% inflation target is nonnegotiable, the independence of the Federal Reserve is nonnegotiable, and that policies must be "fought out" in the meeting room. Therefore, this is not a dovish pivot, but rather keeping the options open—which makes the market uncomfortable.
Second Shot (Ending Forward Guidance/Dot Plot): The Fed will no longer give the market answers
Walsh hinted that the dot plot may gradually be de-emphasized or even reformed in the future. He also hopes that in the next 9 to 12 months, the Federal Reserve can rely more on real-time data, rather than depending solely on lagging government data and surveys. This means the Fed is rebuilding its reaction function. In the past, the market looked at the dot plot to know "where the Fed itself thought rates were headed." In the future, the market will focus on the data to guess "how the Fed will react to these data." The difference is significant: the dot plot anchored the market, while real-time data fuels volatility. The less the Fed communicates, the more data-driven volatility the market will see.
Third Shot (Normalization of High Interest Rates): Refusing to give the market rate cut fantasies
He emphasized the 2% inflation target and kept the possibility of rate hikes on the table, which will keep U.S. rates elevated. What the market is really trading is not what Walsh said—but what he refused to say. In the short term, Walsh’s comments appear to ease inflation worries, but they do not truly release liquidity.
Walsh didn’t tell the market what the next step will be, but he made it clear that in the future he won’t easily tell you what the next step will be. He offered some gentle words but at the same time took back what the market relies on the most: certainty.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India
Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge
The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales
Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

